



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12Q 1/68	A1	(11) International Publication Number: WO 00/15849 (43) International Publication Date: 23 March 2000 (23.03.00)
(21) International Application Number: PCT/US99/21087 (22) International Filing Date: 15 September 1999 (15.09.99) (30) Priority Data: 60/100,305 15 September 1998 (15.09.98) US (71) Applicant: YALE UNIVERSITY [US/US]; 451 College Street, New Haven, CT 06511 (US). (72) Inventor: LIZARDI, Paul, M.; 350 Mountain Road, Hamden, CT 06514 (US). (74) Agents: PABST, Patrea, L. et al.; Arnall Golden & Gregory, LLP, 2800 One Atlantic Center, 1201 West Peachtree Street, Atlanta, GA 30309-3450 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: ARTIFICIAL LONG TERMINAL REPEAT VECTORS		
(57) Abstract <div style="display: flex;"> <div style="flex: 1;"> <p>Disclosed are compositions and an in vitro method for cloning and/or amplification of nucleic acid sequences of interest. The method is based on strand displacement replication of the nucleic acid sequences by multiple priming on artificial long terminal repeat (ALTR) sequences appended to the ends of the nucleic acid molecule of interest. The nucleic acid molecules for cloning and amplification can be very long, up to 40 to 80 Kb or longer. In a preferred form of the method, a single primer is used to prime strand displacement replication at multiple sites in artificial long terminal repeat sequences, flanking a target nucleic acid, containing multiple tandem repeats of a primer complement sequence. Amplification proceeds by replication initiated at each primer and continuing through the target nucleic acid sequence. This nested replication of multiple copies significantly increases the amplification yield for extremely long nucleic acid molecules. By using a sufficient number of repeat units in the ALTRs, only a few rounds of replication are required to produce hundreds of thousands of copies of the nucleic acid sequence of interest. A preferred form of the disclosed method makes use of indexed artificial long terminal repeats that allow amplification and identification of specific nucleic acid fragments present in a mixture of nucleic acid fragments without requiring any knowledge of the sequence of the nucleic acid fragment.</p> </div> <div style="flex: 2;"> <p>A Rolling circle replication primer Oligonucleotide with recognition sequence for restriction endonuclease and primer sequence complementary to terminal repeat circle Terminal repeat circle Circular DNA containing sequence for generation of ALTR</p> <p>B Generation of single-stranded repeats by rolling circle replication</p> <p>C Generation of second strand by tandem primers</p> <p>D Double-stranded ALTR with tail sequence remains after removal of ssDNA. The ligatable terminus is generated by cleavage with a specific restriction endonuclease</p> </div> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ARTIFICIAL LONG TERMINAL REPEAT VECTORS

BACKGROUND OF THE INVENTION

The disclosed invention is generally in the field of nucleic acid amplification.

5 DNA molecular cloning is routinely carried out using plasmid, phage, or viral vectors that replicate inside cells. Genomic cloning is routinely carried out using vectors that replicate inside cells. While existing cloning methods work quite well for most genomic fragments, certain DNA domains tend to suffer alterations, notably deletions or rearrangements. A method, in
10 which individual DNA molecules are cloned in solution by serial dilution and subsequent PCR amplification from tubes containing single molecules has been described (Lukyanov *et al.*, *Nucleic Acid Research* 24:2194-2195 (1996)). A method has also been described for cloning RNA populations derived from single RNA molecules in an immobilized medium (Chetverina and Chetverin, *Nucleic Acids Research* 21:2349-2353 (1993)). While both
15 of these methods allow *in vitro* cloning, neither is practical for cloning of large fragments.

 A number of methods have been developed for exponential amplification of nucleic acids. These include the polymerase chain reaction
20 (PCR), ligase chain reaction (LCR), self-sustained sequence replication (3SR), nucleic acid sequence based amplification (NASBA), strand displacement amplification (SDA), and amplification with Q β replicase (Birkenmeyer and Mushahwar, *J. Virological Methods*, 35:117-126 (1991); Landegren, *Trends Genetics* 9:199-202 (1993)).

25 Current methods of PCR amplification involve the use of two primers which hybridize to the regions flanking a nucleic acid sequence of interest such that DNA replication initiated at the primers will replicate the nucleic acid sequence of interest. By separating the replicated strands from the template strand with a denaturation step, another round of replication using
30 the same primers can lead to geometric amplification of the nucleic acid sequence of interest. PCR amplification has the disadvantage that the amplification reaction cannot proceed continuously and must be carried out by subjecting the nucleic acid sample to multiple cycles in a series of

reaction conditions. PCR also has the disadvantage that the length of nucleic acid that can be effectively amplified is limited.

Accordingly, there is a need for a cloning and amplification method that allows amplification of longer nucleic acid segments and that is less complicated, are more reliable, and produces greater amplification in a shorter time.

It is therefore an object of the disclosed invention to provide an in vitro method of cloning and amplifying a target nucleic acid sequence in a continuous, isothermal reaction.

It is another object of the disclosed invention to provide an in vitro method of cloning and amplifying a target nucleic acid sequence where multiple copies of the target nucleic acid sequence are produced in a single amplification cycle.

It is another object of the disclosed invention to provide a kit for cloning and amplifying a target nucleic acid sequence in a continuous, isothermal reaction.

BRIEF SUMMARY OF THE INVENTION

Disclosed are compositions and an in vitro method for cloning and/or amplification of nucleic acid sequences of interest. The method is based on strand displacement replication of the nucleic acid sequences by multiple priming on artificial long terminal repeat (ALTR) sequences appended to the ends of the nucleic acid molecule of interest. The target sequences for cloning and amplification can be very long, up to 40 to 80 Kb or longer. In a preferred form of the method, a single primer is used to prime strand displacement replication at multiple sites in artificial long terminal repeat sequences, flanking a target nucleic acid, containing multiple tandem repeats of a primer complement sequence. Amplification proceeds by replication initiated at each primer and continuing through the target nucleic acid sequence.

A key feature of this method is the displacement of intervening primers during replication. Once the nucleic acid strands elongated from the right ALTR reaches the left ALTR, and vice versa, another round of priming and replication will take place. This allows multiple copies of a nested set of

the target nucleic acid sequence to be synthesized in a short period of time.

This nested replication of multiple copies significantly increases the amplification yield for extremely long target sequences since copies of the target sequence are produced simultaneously, not sequentially as in PCR. By using a sufficient number of repeat units in the ALTRs, and thus a sufficient number of primer complement sequences, only a few rounds of replication are required to produce hundreds of thousands of copies of the nucleic acid sequence of interest.

The disclosed method has advantages over the polymerase chain reaction since it can be carried out under isothermal conditions. No thermal cycling is needed because the polymerase at the head of an elongating strand (or a compatible strand-displacement protein) will displace, and thereby make available for hybridization, the strand ahead of it. Other advantages of the disclosed method include the ability to amplify very long nucleic acid segments (on the order of 80 kilobases) and rapid amplification of shorter segments (10 kilobases or less). In the disclosed method, single priming events at unintended sites will not lead to artifactual amplification at these sites (since amplification at the intended site will quickly outstrip the single strand replication at the unintended site).

A preferred form of the disclosed method makes use of indexed artificial long terminal repeats that allow amplification and identification of specific nucleic acid fragments present in a mixture of nucleic acid fragments without requiring any knowledge of the sequence of the nucleic acid fragment. This is accomplished by digesting a nucleic acid sample, such a genomic DNA, with a restriction enzyme having an interrupted palindrome recognition sequence or a cleavage site offset from the recognition site (interrupted palindrome and class-IIS restriction enzymes). The resulting fragments having a random distribution of sticky ends are then ligated to pairs of indexed ALTRs in separate reactions collectively representing every combination of indexed ALTRs. The indexed ALTRs each have a different sticky end and the set of ALTRs collectively include all of the possible sticky ends that can be generated by the restriction enzyme used. Thus, in each ligation reaction, only those nucleic acid fragments having sticky ends

complementary to the sticky ends of the specific pair of ALTRs present in the reaction will have an ALTR added to each end. As a result, only these fragments to which ALTRs have been added will be amplified.

Alternatively, all of the ALTRs can be used together in the same reaction to
5 clone and amplify all of the compatible fragments in a nucleic acid sample. In the resulting mixture of clones, a clone of interest, if identified, can be separately amplified by identifying the ALTRs flanking the clone and using the same ALTRs to clone the fragment individually. Once identified, the same nucleic acid fragment can be cloned from the same source using the
10 same pair of ALTRs that resulting in the original amplification.

Following amplification, the amplified sequences can be for any purpose, such as uses known and established for PCR amplified sequences. For example, amplified sequences can be detected using any of the conventional detection systems for nucleic acids such as detection of
15 fluorescent labels, enzyme-linked detection systems, antibody-mediated label detection, and detection of radioactive labels. The amplified sequences can also be used to long nucleic acids for pharmaceutical uses, such as for multi-antigen vaccines, that are free of contaminating proteins and other cellular components that are present in nucleic acid replicated in cells.

20 A key feature of the disclosed method is that amplification takes place not in cycles, but in a continuous, isothermal replication. This makes amplification less complicated and much more consistent in output. Strand displacement allows rapid generation of multiple copies of a nucleic acid sequence or sample in a single, continuous, isothermal reaction. DNA that
25 has been produced using the disclosed method can then be used for any purpose or in any other method desired. For example, PCR can be used to further amplify any specific DNA sequence that has been previously amplified by the disclosed method.

BRIEF DESCRIPTION OF THE DRAWINGS

30 Figures 1A, 1B, 1C, and 1D are diagrams of steps in the formation of an artificial long terminal repeat using rolling circle replication of a terminal repeat circle.

Figure 2 is a diagram illustrating formation of an artificial long terminal repeat vector.

Figure 3 is a graph of the number of DNA strands generated in the disclosed method versus time when amplifying a 14,000 bp insert using 600 repeat ALTRs.

Figure 4 is a graph of the number of DNA strands generated in the disclosed method versus time when amplifying a 65 kb insert using 48 repeat ALTRs.

DETAILED DESCRIPTION OF THE INVENTION

Disclosed are compositions and an in vitro method for cloning and amplification of nucleic acid sequences of interest. The method is based on strand displacement replication of the nucleic acid sequences by multiple priming on artificial long terminal repeat (ALTR) sequences appended to the ends of the nucleic acid molecule of interest. The target sequences for cloning and amplification can be very long, up to 40 to 80 Kb or longer. In a preferred form of the method, a single primer is used to prime strand displacement replication at multiple sites in artificial long terminal repeat sequences, flanking a target nucleic acid, containing multiple tandem repeats of a primer complement sequence. Amplification proceeds by replication initiated at each primer and continuing through the target nucleic acid sequence.

A key feature of this method is the displacement of intervening primers during replication. Once the nucleic acid strands elongated from the right ALTR reaches the left ALTR, and vice versa, another round of priming and replication will take place. This allows multiple copies of a nested set of the nucleic acid molecule to be synthesized in a short period of time. This nested replication of multiple copies significantly increases the amplification yield for extremely long target sequences since copies of the target sequence are produced simultaneously, not sequentially as in PCR. By using a sufficient number of repeat units in the ALTRs, and thus a sufficient number of primer complement sequences, only a few rounds of replication are required to produce hundreds of thousands of copies of the nucleic acid sequence of interest.

The disclosed method has advantages over the polymerase chain reaction since it can be carried out under isothermal conditions. No thermal cycling is needed because the polymerase at the head of an elongating strand (or a compatible strand-displacement protein) will displace, and thereby
5 make available for hybridization, the strand ahead of it. Other advantages of the disclosed method include the ability to amplify very long nucleic acid segments (on the order of 80 kilobases) and rapid amplification of shorter segments (10 kilobases or less). In the disclosed method, single priming events at unintended sites will not lead to artifactual amplification at these
10 sites (since amplification at the intended site will quickly outstrip the single strand replication at the unintended site).

A preferred form of the disclosed method makes use of indexed artificial long terminal repeats that allow amplification and identification of specific nucleic acid fragments present in a mixture of nucleic acid fragments
15 without requiring any knowledge of the sequence of the nucleic acid fragment. This is accomplished by digesting a nucleic acid sample, such a genomic DNA, with a restriction enzyme having an interrupted palindrome recognition sequence or a cleavage site offset from the recognition site (interrupted palindrome and class-IIIS restriction enzymes). The resulting
20 fragments having a random distribution of sticky ends are then ligated to pairs of indexed ALTRs in separate reactions collectively representing every combination of indexed ALTRs. The indexed ALTRs each have a different sticky end and the set of ALTRs collectively include all of the possible sticky ends that can be generated by the restriction enzyme used. Thus, in each
25 ligation reaction, only those nucleic acid fragments having sticky ends complementary to the sticky ends of the specific pair of ALTRs present in the reaction will have an ALTR added to each end. As a result, only these fragments to which ALTRs have been added will be amplified.

Alternatively, all of the ALTRs can be used together in the same reaction to
30 clone and amplify all of the compatible fragments in a nucleic acid sample. In the resulting mixture of clones, a clone of interest, if identified, can be separately amplified by identifying the ALTRs flanking the clone and using the same ALTRs to clone the fragment individually. Once identified, the

same nucleic acid fragment can be cloned from the same source using the same pair of ALTRs that resulting in the original amplification.

Following amplification, the amplified sequences can be for any purpose, such as uses known and established for PCR amplified sequences.

5 For example, amplified sequences can be detected using any of the conventional detection systems for nucleic acids such as detection of fluorescent labels, enzyme-linked detection systems, antibody-mediated label detection, and detection of radioactive labels. The amplified sequences can also be used to long nucleic acids for pharmaceutical uses, such as for multi-
10 antigen vaccines, that are free of contaminating proteins and other cellular components that are present in nucleic acid replicated in cells.

A key feature of the disclosed method is that amplification takes place not in cycles, but in a continuous, isothermal replication. This makes amplification less complicated and much more consistent in output. Strand
15 displacement allows rapid generation of multiple copies of a nucleic acid sequence or sample in a single, continuous, isothermal reaction. DNA that has been produced using the disclosed method can then be used for any purpose or in any other method desired. For example, PCR can be used to further amplify any specific DNA sequence that has been previously
20 amplified by the disclosed method.

In Nature, certain DNA sequences are known contain direct repeats. Other sequences are known to contain inverted repeats. This disclosed method uses an unnatural object, the Artificial Long Terminal Repeat vector, which contains either the same type of repeats at both ends, or preferably,
25 two different kinds of repeats on either end. The resulting molecule comprises one array of identical repeats on one side, and another array of identical repeats on the other side of a DNA insert (DDDDD). The repeats are joined by linker sequences (LLL or SSS), which may be identical for any given construct (as in example ALTR 1, below), or different for any given
30 construct (as in example ALTRs 2 and 3, below).

Example ALTR vector configurations are illustrated diagrammatically below. In these examples four base repeats were used to save space. The preferred repeat length is much longer, as discussed

elsewhere herein. For all of these configurations, the replication of each DNA strand occurs through the binding and extension of a single DNA primer at multiple sites in the ALTR sequence.

1. ALTR with identical repeats and identical linkers (SEQ ID NO:1)

5 AGGT>AGGT>AGGT>AGGT>AGGT>AGGT>LLL>DDDDDDDDDD
TCCA<TCCA<TCCA<TCCA<TCCA<TCCA>LLL>DDDDDDDDDD
>LLL>ACCT>ACCT>ACCT>ACCT>ACCT>ACCT
<LLL<TGGA<TGGA<TGGA<TGGA<TGGA<TGGA

2. ALTR with identical repeats and different linkers (SEQ ID NO:2)

10 AGGT>AGGT>AGGT>AGGT>AGGT>AGGT>LLL>DDDDDDDDDD
TCCA<TCCA<TCCA<TCCA<TCCA<TCCA>LLL>DDDDDDDDDD
>SSS>ACCT>ACCT>ACCT>ACCT>ACCT>ACCT
<SSS<TGGA<TGGA<TGGA<TGGA<TGGA<TGGA

3. ALTR with two types of ALTR repeats and different linkers (SEQ ID

15 NO:3)
AGGT>AGGT>AGGT>AGGT>AGGT>AGGT>LLL>DDDDDDDDDD
TCCA<TCCA<TCCA<TCCA<TCCA<TCCA>LLL>DDDDDDDDDD
>SSS>GATG>GATG>GATG>GATG>GATG>GATG
<SSS<CTAC<CTAC<CTAC<CTAC<CTAC<CTAC

20 The disclosed method has several advantageous features. A few are listed below.

- a) Can be generated by isothermal amplification starting from a few molecules
- b) Can generate clonal DNA populations in a test tube
- 25 c) No selection against coding sequences that may be deleterious to E. coli
- d) Can be made to incorporate of modified bases as dNTPs
- e) Can be made with chemically modified 5'-termini by simply using suitably modified primers in the amplification reaction.
- 30 f) Simple purification after in vitro synthesis
- g) Increased purity (freedom from bacterial cell contaminants such as pyrogens).

The disclosed method, and the nucleic acid molecules amplified in the disclosed method can be used for a number of purposes. For example:

- 35 1. Gene mapping analysis of genomic DNA or long cDNAs.
- 2. Analysis of chromosomal translocations.

3. Automated manipulation and sequencing of genomic DNA or long cDNAs.

4. Sequencing of genomic DNA

5. Exon trapping of genomic DNA

5 There are a number of other applications which require the use of large DNA molecules. Examples of such applications occur in the field of DNA vaccines. DNA vaccine vectors may contain a number of coding sequences, designed to produce a multiplicity of antigens. As knowledge of vaccine antigens improves, there is a growing tendency to create vectors that
10 combine many antigen-coding genes in a concatenated arrangement. Currently, bacterial plasmids are used as vectors for DNA vaccine construction.

One embodiment of the disclosed method is a method of amplifying a target nucleic acid sequence, where the method involves

15 (a) replicating a terminal repeat circle by rolling circle replication primed by a rolling circle replication primer to form an artificial long terminal repeat,

(b) ligating the artificial long terminal repeat to the ends of a target nucleic acid sequence to form an artificial long terminal repeat vector,

20 (c) amplifying the artificial long terminal repeat vector by strand displacement replication primed by one or more strand displacement primers, where the target nucleic acid sequence is amplified.

Another embodiment of the disclosed method is a method of amplifying a target nucleic acid sequence, where the method involves

25 (a) ligating artificial long terminal repeats to the ends of a target nucleic acid sequence to form an artificial long terminal repeat vector,

(b) amplifying the artificial long terminal repeat vector by strand displacement replication primed by one or more strand displacement primers, where the target nucleic acid sequence is amplified.

30 Another embodiment of the disclosed method is a method of amplifying a target nucleic acid sequence, where the method involves

(a) ligation of multiple identical repeat units to form an artificial long terminal repeat,

(b) ligating the artificial long terminal repeat to the ends of a target nucleic acid sequence to form an artificial long terminal repeat vector,

(c) amplifying the artificial long terminal repeat vector by strand displacement replication primed by one or more strand displacement primers,

5 where the target nucleic acid sequence is amplified.

Another embodiment of the disclosed method is a method of amplifying nucleic acid molecules, where the method involves

(a) digesting a nucleic acid sample with a type II restriction endonuclease having an interrupted palindrome recognition sequence or a
10 type IIS restriction enzyme to produce nucleic acid molecules with cohesive ends,

(b) ligating artificial long terminal repeats to the ends of the nucleic acid molecules to form artificial long terminal repeat vectors,

(c) amplifying the artificial long terminal repeat vectors by strand
15 displacement replication primed by one or more strand displacement primers, where the nucleic acid molecule is amplified.

The method can be practiced and expanded in several ways. For example, the amplification of the artificial long terminal repeat vector can be primed by a single strand displacement primer. The amplification can be
20 performed under substantially isothermic conditions. The amplification can be performed without thermal cycling. The artificial long terminal repeats can each have at least five repeat units. The artificial long terminal repeats can each have at least 25 repeat units. The artificial long terminal repeat can be produced by replicating a terminal repeat circle by rolling circle
25 replication primed by a rolling circle replication primer. The artificial long terminal repeat can be made double-stranded by performing the rolling circle replication in the presence of helicase, primase, ligase, and single-stranded DNA binding protein. The artificial long terminal repeat can be made double-stranded by ligating together oligonucleotides hybridized to the
30 artificial long terminal repeat strand made during the rolling circle replication.

The disclosed method can also use a set of artificial long terminal repeats in step (b), where each member of the set has a different cohesive

end, and where the cohesive ends of the members of the set collectively include complements to all possible cohesive ends that can be generated by cleavage with the restriction endonuclease, such that the artificial long terminal repeat ligated on each end of the nucleic acid molecules depends on the sequences of the cohesive ends of each nucleic acid molecule. In such an embodiment, step (b) can be performed as multiple separate reactions where each reaction has a different pair of artificial long terminal repeats.

Also disclosed is a kit for amplifying a target nucleic acid sequence, the kit including an artificial long terminal repeat, where the artificial long terminal repeat comprises tandem repeat units and a tail sequence at one end, and a strand displacement primer, where the strand displacement primer is complementary to a sequence in, or straddling, the repeat units. The kit can also include a strand displacing DNA polymerase or a DNA polymerase and a compatible strand displacement factor. Also disclosed is a kit for amplifying a target nucleic acid sequence, the kit including a repeat circle, where the repeat circle is a single-stranded circular DNA molecule, a rolling circle replication primer including a sequence complementary to a sequence in the repeat circle, and a tail sequence, and a strand displacement primer, where the strand displacement primer is complementary to a sequence in, or straddling, the repeat units.

I. Materials

A. Nucleic Acid Molecules

Nucleic acid molecules for cloning and amplification in the disclosed method can be any nucleic acid. A nucleic acid molecule for use in the disclosed method can be in any nucleic acid sample of interest. The source, identity, and preparation of many such nucleic acid samples are known. The nucleic acid molecules can come from any source such as a cellular or tissue nucleic acid sample, a subclone of a previously cloned fragment, mRNA, chemically synthesized nucleic acid, genomic nucleic acid samples, nucleic acid molecules obtained from nucleic acid libraries, specific nucleic acid molecules, and mixtures of nucleic acid molecules. Since the disclosed method is particularly suited to amplification of very large molecules (up to 80 Kb or larger), genomic nucleic acid samples are particularly preferred as a

source for nucleic acid molecules. The nucleic acid sample can be a nucleic acid sample from a single cell. Preferred nucleic acid molecules are those which are difficult to amplify using PCR due to, for example, length or composition.

5 In the method, the nucleic acid molecule is flanked by artificial long terminal repeats (ALTRs). Preferably this is accomplished by ligation of the ALTRs to the nucleic acid molecule, although any suitable coupling mechanism can also be used. Thus, the only requirement for nucleic acids molecules to be used in the disclosed method is that they can be coupled to
10 the end of an ALTR. Single-stranded nucleic acid molecules, such as RNA, can be used by converting the molecule to be double-stranded. In the case of RNA molecules, this can be accomplished, for example, by producing a cDNA molecule of the RNA. Numerous methods are known for preparing and inserting nucleic acid molecules into vectors and any of these can be
15 used to prepare nucleic acid molecules for use in the disclosed method (see, for example, Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd Edition (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989)).

 Preferably, the nucleic acid molecule is prepared by generating
20 cohesive ends (sticky ends) to facilitate attachment of ALTRs. This can be accomplished, for example by cleaving a nucleic acid molecule of interest, or a nucleic acid sample, with a restriction enzyme, or by adding linkers to the ends of nucleic acid molecules of interest that have, or can be processed to have sticky ends. One or both of the ends of the nucleic acid molecule can
25 also be left blunt ended, although this is not preferred. The two ends of nucleic acid molecules to be used in the disclosed method can also be made different to allow directional ligation of different ALTRs. For example, the to ends can have different sticky ends, or have one sticky end and one blunt end.

30 For cloning with indexed artificial long terminal repeats, the nucleic acid molecules should be prepared by cleavage with a restriction enzyme having an interrupted palindrome or a cleavage site that is offset from the recognition sequence. Preferred restriction enzymes having an interrupted

palindrome are type II restriction enzymes having degeneracy in the recognition/cleavage sequence around the site of cleavage. Preferred restriction enzymes having a cleavage site that is offset from the recognition sequence are type IIS restriction enzymes. These restriction enzymes will
5 produce nucleic acid molecules having a distribution of sequences represented in their cohesive ends. This allows ligation of different indexed ALTRs depending on the actual sequence of the cohesive ends present on a given nucleic acid molecule.

B. Rolling Circle Replication Primers

10 Rolling circle replication primers are used with the disclosed method to produce artificial long terminal repeats by priming rolling circle replication of terminal repeat circles. A rolling circle replication primer (RCRP) is an oligonucleotide having sequence complementary to the primer complement portion of a terminal repeat circle. This sequence is referred to
15 as the complementary portion of the RCRP. The complementary portion of a RCRP and the cognate primer complement portion can have any desired sequence so long as they are complementary to each other. In general, the sequence of the RCRP can be chosen such that it is not significantly complementary to any other portion of the terminal repeat circle. The
20 complementary portion of a rolling circle replication primer can be any length that supports specific and stable hybridization between the primer and the primer complement portion. Generally this is 10 to 35 nucleotides long, but is preferably 16 to 20 nucleotides long.

It is preferred that rolling circle replication primers also contain
25 additional sequence at the 5' end of the RCRP that is not complementary to any part of the terminal repeat circle. This sequence is referred to as the tail sequence of the RCRP. The tail sequence preferably contains one or more restriction sites for cleavage by restriction enzymes. These sites serve to facilitate ligation of artificial long terminal repeats to nucleic acid molecules.
30 This purpose is aided by the location of the tail sequence at the end of ALTR sequence produced by rolling circle replication primed by the rolling circle replication primer.

The tail sequence of the RCRP also serves to facilitate strand displacement during DNA replication. The tail sequence of a RCRP may be any length, but is generally 1 to 200 nucleotides long, and preferably 30 to 100 nucleotides long. The rolling circle replication primer may also include
5 modified nucleotides to make it resistant to exonuclease digestion. For example, the primer can have three or four phosphorothioate linkages between nucleotides at the 5' end of the primer.

C. Strand Displacement Primers

Strand displacement primers for use in the disclosed amplification
10 method are oligonucleotides having sequence complementary to sequence in, or straddling, the repeat unit of the artificial long terminal repeat. This sequence is referred to as the complementary portion of the strand displacement primer. This relationship ensures that there are multiple primer complement sequences in the ALTR (one for every repeat unit in the ALTR).
15 The complementary portion of a strand displacement primer can be any length that supports specific and stable hybridization between the strand displacement primer and the ALTR. Generally this is 10 to 35 nucleotides long, but is preferably 16 to 24 nucleotides long.

It is preferred that strand displacement primers also contain additional
20 sequence at the 5' end of the strand displacement primer that is not complementary to the ALTR. This sequence is referred to as the non-complementary portion of the strand displacement primer. The non-complementary portion of the strand displacement primer, if present, serves to facilitate strand displacement during DNA replication. The non-
25 complementary portion of the strand displacement primer can also include a functional sequence such as a promoter for an RNA polymerase. The non-complementary portion of a strand displacement primer may be any length, but is generally 1 to 100 nucleotides long, and preferably 4 to 8 nucleotides long.

30 It is preferred that, when hybridized to an ALTR, the strand displacement primers are separated from each other. The amount of separation between adjacent, hybridized strand displacement primers is a function of the length of the repeat unit and the length of the complementary

portion of the primer. The longer the repeat unit, the greater the separation.

The longer the complementary portion of the primer, the shorter the separation. It is preferred that, when hybridized, the strand displacement primers are separated from each other by at least 5 bases. It is more

5 preferred that, when hybridized, the strand displacement primers are separated from each other by at least 10 bases. It is still more preferred that, when hybridized, the strand displacement primers are separated from each other by at least 20 bases. It is still more preferred that, when hybridized, the strand displacement primers are separated from each other by at least 30
10 bases. It is still more preferred that, when hybridized, the strand displacement primers are separated from each other by at least 40 bases. It is still more preferred that, when hybridized, the strand displacement primers are separated from each other by at least 50 bases.

It is preferred that, when hybridized, the strand displacement primers
15 are separated from each other by no more than about 500 bases. It is more preferred that, when hybridized, the strand displacement primers are separated from each other by no more than about 400 bases. It is still more preferred that, when hybridized, the strand displacement primers are separated from each other by no more than about 300 bases. It is still more
20 preferred that, when hybridized, the strand displacement primers are separated from each other by no more than about 200 bases. Any combination of the preferred upper and lower limits of separation described above are specifically contemplated, including all intermediate ranges. There need not be any separation between strand displacement primers.

25 The optimal separation distance between strand displacement primers will not be the same for all DNA polymerases, because this parameter is dependent on the net polymerization rate. A processive DNA polymerase will have a characteristic polymerization rate which may range from 5 to 300 nucleotides per second, and may be influenced by the presence or absence of
30 accessory ssDNA binding proteins and helicases. In the case of a non-processive polymerase, the net polymerization rate will depend on the enzyme concentration, because at higher concentrations there are more re-initiation events and thus the net polymerization rate will be increased. An

example of a processive polymerase is ϕ 29 DNA polymerase, which proceeds at 50 nucleotides per second. An example of a non-processive polymerase is Vent exo(-) DNA polymerase, which will give effective polymerization rates of 4 nucleotides per second at low concentration, or 16
5 nucleotides per second at higher concentrations.

To obtain an optimal yield in a strand displacement replication reaction, the primer spacing is preferably adjusted to suit the polymerase being used. Long primer spacing is preferred when using a polymerase with a rapid polymerization rate. Shorter primer spacing is preferred when using
10 a polymerase with a slower polymerization rate. The following assay can be used to determine optimal spacing with any polymerase. The artificial long terminal repeats are designed for the same strand displacement primer, but with different repeat unit lengths. The repeat unit length is varied systematically between in increments of 25 nucleotides within the range of
15 10 nucleotides to 410 nucleotides. A series of reactions are performed in which the different ALTR vectors are amplified using the same strand displacement primer. The spacing that produces the highest experimental yield of DNA is the optimal primer spacing for the specific DNA
polymerase, or DNA polymerase plus accessory protein combination being
20 used.

DNA replication initiated at the sites in the ALTR vector where the primers hybridize will extend to and displace strands being replicated from primers hybridized at adjacent sites. Displacement of an adjacent strand makes it available for hybridization to another primer and subsequent
25 initiation of another round of replication.

Where indexed ALTRs are used, the strand displacement primer is preferably a single universal primer that can prime all of the ALTRs. For specific amplification in a mixture of ALTR vectors using a mixture of indexed ALTRs, a strand displacement primer specific for a specific ALTR
30 may be used. Such a strand displacement primer is referred to as an indexed strand displacement primer. This can be accomplished by including both common sequences (common to all of the indexed ALTRs) and individual sequences (each present only in one of the indexed ALTRs) in the repeat

units of the indexed ALTRs. The complementary portions of the indexed strand displacement primers are complementary to an individual sequence in one (or a subset) of the indexed ALTRs.

Since indexed ALTRs are used in pairs, the strand displacement
5 primers may consist of a universal pair of primers, one designed to bind the first ALTR and the other designed to bind the second ALTR of each indexing pair. In such embodiments, there is one universal primer specific for the first strand, and one (different) universal primer specific for the second strand. This universal set of two primers may be used for all pairs of
10 ALTRs.

D. Terminal Repeat Circles

An terminal repeat circle (TRC) is a circular single-stranded DNA molecule, generally containing between 40 to 1000 nucleotides, preferably between about 50 to 150 nucleotides, and most preferably between about 50
15 to 100 nucleotides. Portions of TRCs have specific functions making the TRC useful for production of artificial long terminal repeats (ALTRs). Generally, an terminal repeat circle is a single-stranded, circular DNA molecule comprising a primer complement portion and a primer portion. The primer complement portion is complementary to the complementary
20 portion of a rolling circle replication primer. The primer portion matches the complementary portion of a strand displacement primer. This arrangement allows strand displacement primers to prime synthesis from the ALTRs into the nucleic acid molecule flanked by the ALTRs.

Those segments of the TRC that do not correspond to a specific
25 portion of the TRC can be arbitrarily chosen sequences. It is preferred that TRCs do not have any sequences that are self-complementary. It is considered that this condition is met if there are no complementary regions greater than six nucleotides long without a mismatch or gap. It is also preferred that TRCs containing a promoter portion do not have any
30 sequences that resemble a transcription terminator, such as a run of eight or more thymidine nucleotides.

A terminal repeat circle, when replicated, gives rise to a long DNA molecule containing multiple repeats of sequences complementary to the

terminal repeat circle. This long DNA molecule is referred to herein as an artificial long terminal repeat (ALTR). An ALTR contains sequences complementary to the primer complement portions. These sequences in the ALTR are referred to as rolling circle primer sequences (which match the sequence of the rolling circle replication primer) and strand displacement primer complement sequences (which are complementary to the strand displacement primer).

Where indexed ALTRs are used, there is a terminal repeat circle for each indexed ALTR. Each indexed TRC can include both a common primer portion (common to all TRCs) and an indexed primer portion having an individual sequence for each indexed TRC. This allows strand displacement replication of all indexed ALTR vectors with a universal strand displacement primer, or strand displacement replication of individual indexed ALTR vectors using a strand displacement primer specific for the specific indexed ALTR.

E. Artificial Long Terminal Repeats

Artificial long terminal repeats (ALTRs) are long nucleic acid molecules with tandemly repeated sequences. Each instance of the repeated sequence is referred to as a repeat unit. ALTRs have a tail sequence at one end to facilitate attachment of the ALTR to a nucleic acid molecule of interest. ALTRs are used in the disclosed method to prime strand displacement replication of a nucleic acid molecule flanked by the ALTRs. ALTRs are preferably produced by rolling circle replication of a single-stranded, circular DNA molecule referred to as a terminal repeat circle. The sequence of the repeat unit in an ALTR is the same as the sequence in the terminal repeat circle used to make the ALTR.

The tail sequence of an ALTR provides an end that can be coupled to the end of a nucleic acid molecule of interest. Preferably, the tail sequence includes one or more restriction enzyme sites that can be cleaved to allow directed ligation of the ALTR to the end of a nucleic acid molecule. The tail sequence appears on only one end of the ALTR to facilitate flanking of nucleic acid molecules with ALTRs. The other end of the ALTR, which should not be capable of ligation to the nucleic acid molecule, will form the

ends of the artificial long terminal repeat vector that results when a nucleic acid molecule is flanked by ALTRs.

An artificial long terminal repeat can include any desired number of repeat units. In general, the more repeat units present, the greater the level of amplification that will be obtained. There is no fundamental upper limit to the number of repeat units that an ALTR can have. It is preferred that an ALTR include from 7 to 50 repeat units. It is preferred that an ALTR include at least 50 repeat units. It is still more preferred that an ALTR include at least 100 repeat units. It is more preferred that an ALTR include at least 200 repeat units. It is more preferred that an ALTR include at least 300 repeat units. It is more preferred that an ALTR include at least 400 repeat units. It is most preferred that an ALTR include at least 600. Any combination of the preferred upper and lower limits for the number of primers in a set of primers described above are specifically contemplated, including all intermediate ranges.

ALTRs can also be made by direct synthesis or concatenation of repeat units. Direct synthesis is preferably accomplished by making two oligonucleotides where the 5' half of the first oligonucleotide is complementary to the 5' half of the second oligonucleotide, and the 3' half of the first oligonucleotide is complementary to the 3' half of the second oligonucleotide. This arrangement allows copies of the oligonucleotides to hybridize too each other in an overlapping chain that can be ligated to form a long, tandem repeat nucleic acid molecule.

F. DNA polymerases

DNA polymerases useful in the disclosed method must be capable of displacing, either alone or in combination with a compatible strand displacement factor, a hybridized strand encountered during replication. Such polymerases are referred to herein as strand displacement DNA polymerases. It is preferred that a strand displacement DNA polymerase lack a 5' to 3' exonuclease activity. Strand displacement is necessary to result in synthesis of multiple copies of a nucleic acid molecule. A 5' to 3' exonuclease activity, if present, might result in the destruction of a synthesized strand. It is also preferred that DNA polymerases for use in the

disclosed method are highly processive. The suitability of a DNA polymerase for use in the disclosed method can be readily determined by assessing its ability to carry out strand displacement replication. Preferred strand displacement DNA polymerases are Bst large fragment DNA polymerase (Exo(-) Bst; Aliotta *et al.*, *Genet. Anal. (Netherlands)* **12**:185-195 (1996)) and exo(-)Bca DNA polymerase (Walker and Linn, *Clinical Chemistry* **42**:1604-1608 (1996)). Other useful polymerases include bacteriophage ϕ 29 DNA polymerase (U.S. Patent Nos. 5,198,543 and 5,001,050 to Blanco *et al.*), phage M2 DNA polymerase (Matsumoto *et al.*, *Gene* **84**:247 (1989)), phage ϕ PRD1 DNA polymerase (Jung *et al.*, *Proc. Natl. Acad. Sci. USA* **84**:8287 (1987)), exo(-)VENT® DNA polymerase (Kong *et al.*, *J. Biol. Chem.* **268**:1965-1975 (1993)), Klenow fragment of DNA polymerase I (Jacobsen *et al.*, *Eur. J. Biochem.* **45**:623-627 (1974)), T5 DNA polymerase (Chatterjee *et al.*, *Gene* **97**:13-19 (1991)), Sequenase (U.S. Biochemicals), PRD1 DNA polymerase (Zhu and Ito, *Biochim. Biophys. Acta* **1219**:267-276 (1994)), and T4 DNA polymerase holoenzyme (Kaboord and Benkovic, *Curr. Biol.* **5**:149-157 (1995)). Exo(-)Bst DNA polymerase is most preferred.

Strand displacement can be facilitated through the use of a strand displacement factor, such as helicase. It is considered that any DNA polymerase that can perform strand displacement replication in the presence of a strand displacement factor is suitable for use in the disclosed method, even if the DNA polymerase does not perform strand displacement replication in the absence of such a factor. Strand displacement factors useful in strand displacement replication include BMRF1 polymerase accessory subunit (Tsurumi *et al.*, *J. Virology* **67**(12):7648-7653 (1993)), adenovirus DNA-binding protein (Zijderveld and van der Vliet, *J. Virology* **68**(2):1158-1164 (1994)), herpes simplex viral protein ICP8 (Boehmer and Lehman, *J. Virology* **67**(2):711-715 (1993); Skaliter and Lehman, *Proc. Natl. Acad. Sci. USA* **91**(22):10665-10669 (1994)); single-stranded DNA binding proteins (SSB; Rigler and Romano, *J. Biol. Chem.* **270**:8910-8919 (1995)); phage T4 gene 32 protein (Villemain and Giedroc, *Biochemistry* **35**:14395-

14404 (1996); and calf thymus helicase (Siegel *et al.*, *J. Biol. Chem.* 267:13629-13635 (1992)).

A useful assay for selecting a polymerase is the primer-block assay described in Kong *et al.*, *J. Biol. Chem.* 268:1965-1975 (1993). The assay
5 consists of a primer extension assay using an M13 ssDNA template in the presence or absence of an oligonucleotide that is hybridized upstream of the extending primer to block its progress. Enzymes able to displace the blocking primer in this assay are useful for the disclosed method.

G. DNA ligases

10 Any DNA ligase is suitable for use in the disclosed method. Preferred ligases are those that preferentially form phosphodiester bonds at nicks in double-stranded DNA. That is, ligases that fail to ligate the free ends of single-stranded DNA at a significant rate are preferred. Thermostable ligases are especially preferred. Many suitable ligases are known, such as T4 DNA
15 ligase (Davis *et al.*, *Advanced Bacterial Genetics - A Manual for Genetic Engineering* (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1980)), *E. coli* DNA ligase (Panasnko *et al.*, *J. Biol. Chem.* 253:4590-4592 (1978)), AMPLIGASE® (Kalin *et al.*, *Mutat. Res.*, 283(2):119-123 (1992); Winn-Deen *et al.*, *Mol Cell Probes* (England) 7(3):179-186 (1993)), Taq
20 DNA ligase (Barany, *Proc. Natl. Acad. Sci. USA* 88:189-193 (1991)), *Thermus thermophilus* DNA ligase (Abbott Laboratories), *Thermus scotoductus* DNA ligase and *Rhodothermus marinus* DNA ligase (Thorbjarnardottir *et al.*, *Gene* 151:177-180 (1995)). T4 DNA ligase is preferred for ligations involving RNA target sequences due to its ability to
25 ligate DNA ends involved in DNA:RNA hybrids (Hsuih *et al.*, *Quantitative detection of HCV RNA using novel ligation-dependent polymerase chain reaction*, American Association for the Study of Liver Diseases (Chicago, IL, November 3-7, 1995)).

H. Detection Labels

30 To aid in detection and quantitation of nucleic acids amplified using the disclosed method, detection labels can be directly incorporated into amplified nucleic acids or can be coupled to detection molecules. As used herein, a detection label is any molecule that can be associated with

amplified nucleic acid, directly or indirectly, and which results in a measurable, detectable signal, either directly or indirectly. Many such labels for incorporation into nucleic acids or coupling to nucleic acid probes are known to those of skill in the art. Examples of detection labels suitable for use in the disclosed method are radioactive isotopes, fluorescent molecules, phosphorescent molecules, enzymes, antibodies, and ligands.

Examples of suitable fluorescent labels include fluorescein (FITC), 5,6-carboxymethyl fluorescein, Texas red, nitrobenz-2-oxa-1,3-diazol-4-yl (NBD), coumarin, dansyl chloride, rhodamine, 4'-6-diamidino-2-phenylindole (DAPI), and the cyanine dyes Cy3, Cy3.5, Cy5, Cy5.5 and Cy7. Preferred fluorescent labels are fluorescein (5-carboxyfluorescein-N-hydroxysuccinimide ester) and rhodamine (5,6-tetramethyl rhodamine). Preferred fluorescent labels are FITC and the cyanine dyes Cy3, Cy3.5, Cy5, Cy5.5 and Cy7. The absorption and emission maxima, respectively, for these fluors are: FITC (490 nm; 520 nm), Cy3 (554 nm; 568 nm), Cy3.5 (581 nm; 588 nm), Cy5 (652 nm; 672 nm), Cy5.5 (682 nm; 703 nm) and Cy7 (755 nm; 778 nm), thus allowing their simultaneous detection. The fluorescent labels can be obtained from a variety of commercial sources, including Molecular Probes, Eugene, OR and Research Organics, Cleveland, Ohio.

Labeled nucleotides are a preferred form of detection label since they can be directly incorporated into the amplification products during synthesis. Examples of detection labels that can be incorporated into amplified DNA or RNA include nucleotide analogs such as BrdUrd (Hoy and Schimke, *Mutation Research* **290**:217-230 (1993)), BrUTP (Wansick *et al.*, *J. Cell Biology* **122**:283-293 (1993)) and nucleotides modified with biotin (Langer *et al.*, *Proc. Natl. Acad. Sci. USA* **78**:6633 (1981)) or with suitable haptens such as digoxigenin (Kerkhof, *Anal. Biochem.* **205**:359-364 (1992)). Suitable fluorescence-labeled nucleotides are Fluorescein-isothiocyanate-dUTP, Cyanine-3-dUTP and Cyanine-5-dUTP (Yu *et al.*, *Nucleic Acids Res.*, **22**:3226-3232 (1994)). A preferred nucleotide analog detection label for DNA is BrdUrd (BUDR triphosphate, Sigma), and a preferred nucleotide analog detection label for RNA is Biotin-16-uridine-5'-triphosphate (Biotin-16-dUTP, Boehringer Mannheim). Fluorescein, Cy3, and Cy5 can be

linked to dUTP for direct labelling. Cy3.5 and Cy7 are available as avidin or anti-digoxigenin conjugates for secondary detection of biotin- or digoxigenin-labelled probes.

5 Detection labels that are incorporated into amplified nucleic acid, such as biotin, can be subsequently detected using sensitive methods well-known in the art. For example, biotin can be detected using streptavidin-alkaline phosphatase conjugate (Tropix, Inc.), which is bound to the biotin and subsequently detected by chemiluminescence of suitable substrates (for example, chemiluminescent substrate CSPD: disodium, 3-(4-methoxyspiro-
10 [1,2,-dioxetane-3-2'-(5'-chloro)tricyclo [3.3.1.1^{3,7}]decane]-4-yl) phenyl phosphate; Tropix, Inc.).

A preferred detection label for use in detection of amplified RNA is acridinium-ester-labeled DNA probe (GenProbe, Inc., as described by Arnold *et al.*, *Clinical Chemistry* **35**:1588-1594 (1989)). An acridinium-
15 ester-labeled detection probe permits the detection of amplified RNA without washing because unhybridized probe can be destroyed with alkali (Arnold *et al.* (1989)).

Molecules that combine two or more of these detection labels are also considered detection labels. Any of the known detection labels can be used
20 with the disclosed probes, tags, and method to label and detect nucleic acid amplified using the disclosed method. Methods for detecting and measuring signals generated by detection labels are also known to those of skill in the art. For example, radioactive isotopes can be detected by scintillation counting or direct visualization; fluorescent molecules can be detected with
25 fluorescent spectrophotometers; phosphorescent molecules can be detected with a spectrophotometer or directly visualized with a camera; enzymes can be detected by detection or visualization of the product of a reaction catalyzed by the enzyme; antibodies can be detected by detecting a secondary detection label coupled to the antibody. As used herein, detection
30 molecules are molecules which interact with amplified nucleic acid and to which one or more detection labels are coupled.

I. Oligonucleotide synthesis

Primers, terminal repeat circles, and any other oligonucleotides can be synthesized using established oligonucleotide synthesis methods. Methods to produce or synthesize oligonucleotides are well known in the art. Such methods can range from standard enzymatic digestion followed by nucleotide fragment isolation (see for example, Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd Edition (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989) Chapters 5, 6) to purely synthetic methods, for example, by the cyanoethyl phosphoramidite method using a Milligen or Beckman System 1Plus DNA synthesizer (for example, Model 8700 automated synthesizer of Milligen-Bioscience, Burlington, MA or ABI Model 380B). Synthetic methods useful for making oligonucleotides are also described by Ikuta *et al.*, *Ann. Rev. Biochem.* **53**:323-356 (1984), (phosphotriester and phosphite-triester methods), and Narang *et al.*, *Methods Enzymol.*, **65**:610-620 (1980), (phosphotriester method). Protein nucleic acid molecules can be made using known methods such as those described by Nielsen *et al.*, *Bioconjug. Chem.* **5**:3-7 (1994).

Many of the oligonucleotides described herein are designed to be complementary to certain portions of other oligonucleotides or nucleic acids such that stable hybrids can be formed between them. The stability of these hybrids can be calculated using known methods such as those described in Lesnick and Freier, *Biochemistry* **34**:10807-10815 (1995), McGraw *et al.*, *Biotechniques* **8**:674-678 (1990), and Rychlik *et al.*, *Nucleic Acids Res.* **18**:6409-6412 (1990).

The materials described above can be packaged together in any suitable combination as a kit useful for performing the disclosed method.

II. Method

The disclosed method is based on strand displacement replication of nucleic acid sequences by multiple primers. The disclosed method generally involves attachment of artificial long terminal repeats (ALTRs) to a nucleic acid molecule and replication of the nucleic acid molecule primed by the primers that hybridize to the repeat sequence in the ALTR. During replication, the growing replicated strands displace other replicated strands

from the nucleic acid molecule (or from another replicated strand) via strand displacement replication. As used herein, a replicated strand is a nucleic acid strand resulting from elongation of a primer hybridized to a nucleic acid molecule or to another replicated strand. Strand displacement replication refers to DNA replication where a growing end of a replicated strand encounters and displaces another strand from the template strand (or from another replicated strand). Displacement of replicated strands by other replicated strands is a hallmark of the disclosed method which allows multiple copies of a nucleic acid molecule to be made in a single, isothermal reaction.

A. Production of Artificial Long Terminal Repeats

ALTRs are preferably produced by rolling circle replication of a single-stranded, circular DNA molecule referred to as a terminal repeat circle. Rolling circle replication requires the use of two reagents: (a) a rolling circle replication primer, which is complementary to the primer complement portion of the terminal repeat circle, and (b) a strand displacement DNA polymerase. The DNA polymerase catalyzes primer extension and strand displacement in a processive rolling circle polymerization reaction that proceeds as long as desired, generating a molecule of up to 100,000 nucleotides or larger. The product of rolling circle replication is a single-stranded artificial long terminal repeat. The sequence of the repeat unit in an ALTR is the same as the sequence in the terminal repeat circle used to make the ALTR. The number of repeat units in the ALTR is determined by the size of the repeat unit, the rate of replication, and the amount of time the reaction is run.

To efficiently attach the ALTR to nucleic acid molecules, the single-stranded ALTR should be converted to a double-stranded ALTR, in whole or in part. The single-stranded ALTR that results from rolling circle replication can be made double-stranded in a variety of ways. Preferably, the single-stranded artificial long terminal repeat can be made double-stranded by performing the rolling circle replication in the presence of helicase, primase, ligase, and single-stranded DNA binding protein. These are the components necessary for lagging strand synthesis in DNA replication (Lee et al.,

Molecular Cell 1:1001-1010 (1998)). As the ALTR strand is synthesized during rolling circle replication, the primase primes lagging strand synthesis, the DNA polymerase extends the lagging strand, and ligase ligates the adjacent Okazaki fragments together. For this means of synthesis for the second strand of the ALTR, the repeat units (and thus also the terminal repeat circle) should contain a priming sequence recognized by the primase (Lee et al.). Preferably, the synthesis of the ALTR occurs in 2 minutes, and is stopped by the addition of a mixture of ddNTPs. The reaction is then incubated for another 30 minutes in the presence of ligase to complete the ligation of the Okazaki fragments.

The artificial long terminal repeat can also be made double-stranded by ligating together oligonucleotides hybridized to the single-stranded artificial long terminal repeat strand made during the rolling circle replication. For this purpose, linear oligonucleotides of the same length and sequence as the terminal repeat circle are preferred. Shorter oligonucleotide (matching part of the sequence of the terminal repeat circle) can also be used, with the gaps between the hybridized oligonucleotides filled in with DNA polymerase (and the nicks ligated). The tail sequence of an ALTR can be designed to leave a convenient cohesive end to allow direct ligation of the ALTR to a nucleic acid molecule. Alternatively, the oligonucleotide can be designed to produce a sufficient double-stranded region to allow digestion with an appropriate restriction enzyme.

ALTRs can also be made by direct synthesis or concatenation of repeat units. Direct synthesis is preferably accomplished by making two oligonucleotides where the 5' half of the first oligonucleotide is complementary to the 5' half of the second oligonucleotide, and the 3' half of the first oligonucleotide is complementary to the 3' half of the second oligonucleotide. This arrangement allows copies of the oligonucleotides to hybridize to each other in an overlapping chain that can be ligated to form a long, tandem repeat nucleic acid molecule.

B. Ligation of Artificial Long Terminal Repeats to Nucleic Acid Molecules

The tail sequence of an ALTR provides an end that can be coupled to the end of a nucleic acid molecule of interest. Preferably, the tail sequence includes one or more restriction enzyme sites that can be cleaved to allow directed ligation of the ALTR to the end of a nucleic acid molecule. The tail sequence appears on only one end of the ALTR to facilitate flanking of nucleic acid molecules with ALTRs. The other end of the ALTR, which should not be capable of ligation to the nucleic acid molecule, will form the ends of the artificial long terminal repeat vector that results when a nucleic acid molecule is flanked by ALTRs.

Numerous methods are known for preparing and inserting nucleic acid molecules into vectors and any of these can be used to prepare nucleic acid molecules for use in the disclosed method (see, for example, Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd Edition (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989)).

Preferably, the nucleic acid molecule is prepared by generating cohesive ends (sticky ends) to facilitate attachment of the ALTR to the nucleic acid molecule. This can be accomplished, for example by cleaving a nucleic acid molecule of interest, or a nucleic acid sample, with a restriction enzyme, or by adding linkers to the ends of nucleic acid molecules of interest that have, or can be processed to have sticky ends. The ALTR should be cleaved to present a compatible cohesive end. One or both of the ends of the nucleic acid molecule can also be left blunt ended, although this is not preferred. The two ends of nucleic acid molecules to be used in the disclosed method can also be made different to allow directional ligation of different ALTRs. For example, the two ends can have different sticky ends, or have one sticky end and one blunt end.

When two different ALTRs are ligated on either side of a DNA insert, two different primers are required for amplification. Upon denaturation of the DNA strands with the two different ALTRs, the rate of DNA renaturation is slow because interactions are exclusively inter-molecular. By contrast, upon denaturation of the DNA strands bounded by the same ALTR, the rate

of DNA renaturation is fast because interactions are intra-molecular. Thus, inserts bounded by two different ALTRs should be replicated more efficiently than inserts bounded by identical ALTRs, due to the greater availability of single-stranded repeats in the first case.

- 5 For cloning with indexed artificial long terminal repeats, the nucleic acid molecules should be prepared by cleavage with a restriction enzyme having an interrupted palindrome or a cleavage site that is offset from the recognition sequence. Preferred restriction enzymes having an interrupted
10 palindrome are type II restriction enzymes having degeneracy in the recognition/cleavage sequence around the site of cleavage. Preferred restriction enzymes having a cleavage site that is offset from the recognition sequence are type IIS restriction enzymes. These restriction enzymes will produce nucleic acid molecules having a distribution of sequences represented in their cohesive ends. This allows ligation of different indexed
15 ALTRs depending on the actual sequence of the cohesive ends present on a given nucleic acid molecule.

An example of the central portion of an assembled ALTR vector is depicted below. The left side ALTR uses repeat A which hybridizes to primer A. The right side ALTR uses repeat B which hybridizes to primer B.

- 20 Repeat A (34 bases) (SEQ ID NO: 4)
ACGCAGCTCGTGTAATACGACTCGCATGCCTCCC
Primer A (22 bases) (SEQ ID NO: 5)
CGCAGCTCGTGTAATACGACTC
Repeat B (34 bases) (SEQ ID NO: 6)
25 ATGCATGCTCAGTGGTGCTGAGTAACAGCCTGGG
Primer B (22 bases) (SEQ ID NO: 7)
GGCTGTTACTCAGCACCCTGA

Left side of ALTR vector (SEQ ID NO:8) with primers aligned (two repeats shown). NNNNNNN represents insert and polylinker sequences.

30

```

5' ACGCAGCTCGTGTAAATACGACTCGCATGCCT
|||||
3' TCGTCGAGCACATTATGCTGAGCGTACGGA
|||||
5' -CGCAGCTCGTGTAAATACGACTC>>>

      CCCACGCAGCTCGTGTAAATACGACTCGCATGCCTCCNNNNNNNN...
      |||||
      GGGTGCCTCGAGCACATTATGCTGAGCGTACGAGGGNNNNNNNN...
10  |||||
      5' -CGCAGCTCGTGTAAATACGACTC>>>

```

Right side of ALTR vector (SEQ ID NO:9) with primers aligned (two repeats shown). NNNNNNN represents insert and polylinker sequences.

```

15  <<<AGTCACCACGACTCATTGTCGG-5'
      |||||
... NNNNNNNNGGGATGCATGCTCAGTGGTGTGAGTAACAGCCTGGGAT
20  |||||
... NNNNNNNCCCTACGTACGAGTCACCACGACTCATTGTCGGACCCTA

      <<<AGTCACCACGACTCATTGTCGG-5'
      |||||
      GCATGCTCAGTGGTGTGAGTAACAGCCT-3'
25  |||||
      CGTACGAGTCACCACGACTCATTGTCGGA-5'

```

C. Strand Displacement Replication

The ALTR vector is amplified by strand displacement replication. In the disclosed method, multiple strand displacement primers hybridize to the primer complement portions of the repeat units in the ALTR. DNA replication initiated at the sites in the ALTR vector where the primers hybridize will extend to and displace strands being replicated from primers hybridized at adjacent sites. Displacement of an adjacent strand makes it available for hybridization to another primer and subsequent initiation of another round of replication. Amplification proceeds by replication initiated at each strand displacement primer and continuing through the nucleic acid molecule. A key feature of this method is the displacement of intervening primers during replication. Once the nucleic acid strands elongated from the right ALTR reaches the left ALTR, and vice versa, another round of priming and replication will take place. This allows multiple copies of a nested set of the target nucleic acid sequence to be synthesized in a short period of time.

Strand displacement replication is preferably accomplished by using a strand displacing DNA polymerase or a DNA polymerase in combination with a compatible strand displacement factor.

By using a sufficient number of repeat units in the ALTRs, only a few rounds of replication are required to produce hundreds of thousands of copies of the nucleic acid sequence of interest. Examples of possible yields are shown in Figures 3 and 4. The disclosed method has advantages over the polymerase chain reaction since it can be carried out under isothermal conditions. No thermal cycling is needed because the polymerase at the head of an elongating strand (or a compatible strand-displacement factor) will displace, and thereby make available for hybridization, the strand ahead of it. Other advantages of strand displacement replication include the ability to amplify very long nucleic acid segments (on the order of 80 kilobases) and rapid amplification of shorter segments (10 kilobases or less). Long nucleic acid segments can be amplified in the disclosed method since there is no cycling which could interrupt continuous synthesis or allow the formation of artifacts due to rehybridization of replicated strands. In strand displacement replication, single priming events at unintended sites will not lead to artifactual amplification at these sites (since amplification at the intended site will quickly outstrip the single strand replication at the unintended site).

Illustrations

The disclosed method can be further appreciated by reference to the following illustrations of examples of the disclosed method.

Illustration 1: The disclosed method (as applied to human genomic DNA derived from a preparation of purified chromosomal DNA) can be performed as follows.

1. Human DNA isolated from a pure preparation of a specific human chromosome (prepared by flow cytometry). The chromosomal DNA is fragmented by partial digestion with either MboI or Sau3AI, and the material is size-fractionated as described by Strong et al. (Nucleic Acids Res., 1997, Vol 25:3959-3961) to yield a DNA fraction in the size range of 55 to 75 kb.

2. Artificial long terminal repeats, containing a restriction enzyme sticky end, and 32 to 64 tandemly repeated sequences of approximately 110

bases, are generated by linear rolling circle replication, as shown in Figure 1. The 32 to 64 repeated sequences are designed to serve as specific priming sites for strand displacement replication in a subsequent step (step 5, below) of the method.

5 3. The DNA is mixed with a 2.5:1 excess of artificial long terminal repeats, and the mixture is ligated to obtain DNA fragments bounded by two ALTRs (Figure 2).

 4. Unligated ALTRs are removed by preparative pulsed-field gel electrophoresis.

10 5. The DNA is mixed with a single strand displacement primer, complementary to the 32-64 repeats of the ALTRs. The mixture is diluted to terminal dilution, such that each well of a microtiter well contains either one or zero molecules of DNA (approximately 30% wells with zero molecules). One may use 20 microtiter dishes of 384 wells for a total of 7680

15 amplification reactions. The material is incubated with a DNA polymerase capable of supporting strand displacement replication, such as Sequenase (mixed with E. Coli SSB) or Bst Large fragment DNA polymerase. The reaction is incubated for a sufficient time (approximately 8 hours) to copy each single DNA molecule 100 million fold or more. Figures 3 and 4 show
20 theoretical kinetics of DNA amplification for 65 kb DNA inserts in an artificial long terminal repeat vector, modeled using Mathematica 3.0.

 6. The DNA generated in each well is isolated and analyzed by restriction enzyme digestion or sequencing.

25 **Illustration 2:** The disclosed method using indexed ALTRs can be performed as follows.

 1. Human DNA isolated from a pure preparation of a specific human chromosome (prepared by flow cytometry). The chromosomal DNA is then digested with an interrupted palindrome enzyme such as SfiI (or an
30 infrequent-cutter class IIS enzyme). The SfiI digest will ideally generate, on the average, 2000 fragments of approximately 40,000 to 95,000 bases each (average size, 65 kb). The fragments may contain any of a possible 64 sticky end sequences.

2. A set of 64 different indexed ALTRs is synthesized, where each indexed ALTR consists of a cohesive SfiI end (3 bases), joined to a sequence of approximately 5000 bases of dsDNA that will serve (after DNA denaturation) as a multiple priming domain. Each multiple priming domain
5 comprises 32 to 50 priming sites of 20 bases plus 90 spacer bases. The tandem sequence thus contains 32 to 50 identical repeats of 110 bases (90+20), whose sequence is uniquely related to one specific cohesive end. In other words, for each cohesive end there is a specific cohesive partner sequence, and an associated tandem priming domain. One or two universal
10 strand displacement primers are used in step 5 below to amplify any sequence bounded by any two indexed ALTRs.

3. The DNA digest is separated in 2016 aliquots, to each of which is added a mixture that contains only one combination of two (out of a possible $64 \times 63/2 = 2016$ different specific combinations) indexed ALTRs. The
15 material is then ligated (Figure 2) to join each combination of two indexers-linkers (more specifically, those which find cohesive partners) to any existing cognate cohesive ends in the chromosomal DNA digest. This procedure can be performed using 6 microtiter dishes of 384 wells. The indexed ALTRs are thus ligated at both termini of each competent DNA
20 fragment (a DNA fragment with perfectly complementary 3-base sticky ends at both termini). Most combinations of 2 indexed ALTRs yield only one (or less frequently two or three) functional (amplifiable) ligated pairs joined to specific DNA fragments, because the number of different chromosomal DNA fragments is approximately 2000 while the number of possible indexed
25 ALTR combinations is 2016.

4. The DNA is purified by QIAEX II (Qiagen, Inc.) to remove the excess of indexed ALTRs, resulting in a preparation of DNA fragments with a linker at each end (these are ALTR vectors). This step may be performed in microtiter wells. An aliquot of the purified material is used for
30 amplification.

5. One or two different universal strand displacement primers are added to each sample of ligated material, and the solution is incubated with a DNA polymerase capable of supporting strand displacement replication, such

as Sequenase (mixed with E. Coli SSB) or Bst Large fragment DNA polymerase. The reaction is incubated for a sufficient time (approximately 6 to 7 hours) to copy each indexed DNA fragment approximately 5 to 10 million fold.

5 6. The DNA generated by strand displacement amplification is fractionated in an agarose gel using a pulsed-field apparatus, and stained with Sybr-Green I to detect bands of amplified material. This gels analysis step is especially useful for reactions where two or three different DNA fragments may be amplified (in most reactions only one fragment should be amplified).

10 7. Optionally, reactions that generate a multiplicity of bands because by chance more than one set of 2 indexers participated in an amplification reaction, may be repeated, starting with the original preparation of linker-DNA, using individual combinations of only 2 indexer primers (out of the possible 10 pairs). Bands comprising a pure amplified fragment, flanked by two unique indexers, are isolated from the pulsed-field agarose gel using QIAEX II (Qiagen, Inc.).

Illustration 3: The disclosed method using two ALTRs and two primers can be performed as follows.

20 1. Human DNA is isolated from a pure preparation of a specific human chromosome (prepared by flow cytometry). The chromosomal DNA is fragmented by partial digestion with a mixture of SpeI (sticky end sequence CTAG) and Xho I (sticky end sequence TCGA), and the material is size-fractionated as described by Strong et al., *Nucleic Acids Res.* 25:3959-3961 (1997), to yield a DNA fraction in the size range of 55 to 75 kb.

25 2. Artificial terminal repeats of two different types, containing two different restriction enzyme sticky ends (SpeI and XhoI), and 32 to 64 tandemly repeated sequences of approximately 40 bases, are generated by ligation of DNA linkers. For each type of sticky end, a different ALTR repeat is used, so that the resulting ALTRs will be different. The 32 to 64 repeated sequences in each of the two types of ALTR are designed to serve as specific priming sites for a strand displacement replication.

3. The DNA is mixed with a 2.5:1 excess of the two types of artificial long terminal repeats (ALTRs), and the mixture is ligated to obtain DNA fragments bounded by two ALTRs. Due to chance, some insets will be bounded by the same ALTRs, while others will be bounded by different
5 ALTRs.

4. Unligated ALTRs are removed by preparative Pulsed-field Gel Electrophoresis.

5. The DNA is mixed with a two universal primers, complementary to the 32-64 repeats of each type of ALTR. The two primers are used at a
10 final concentration of 2 μ M each. The mixture is diluted to terminal dilution, such that each well of a microtiter dish contains either one or zero molecules of DNA (approximately 30% wells with zero molecules). One may use 20 microtiter dishes of 384 wells for a total of 7680 amplification reactions. The material is incubated with a DNA polymerase capable of supporting
15 strand displacement replication, such as Bst Large fragment DNA polymerase. The reaction is incubated at 62°C for a sufficient time (approximately 5 hours) to copy each single DNA molecule one million fold or more. The clones derived from molecules bounded by two different ALTRs are amplified more efficiently than those derived from molecules
20 bounded by identical ALTRs.

6. The DNA generated in each well is isolated and analyzed by restriction enzyme digestion or sequencing.

I claim:

1. A method of amplifying a target nucleic acid sequence, the method comprising:
 - (a) replicating a terminal repeat circle by rolling circle replication primed by a rolling circle replication primer to form an artificial long terminal repeat,
 - (b) ligating the artificial long terminal repeat to the ends of a target nucleic acid sequence to form an artificial long terminal repeat vector,
 - (c) amplifying the artificial long terminal repeat vector by strand displacement replication primed by one or more strand displacement primers,
wherein the target nucleic acid sequence is amplified.
2. The method of claim 1 wherein the amplification of the artificial long terminal repeat vector is primed by a single strand displacement primer.
3. A method of amplifying a target nucleic acid sequence, the method comprising:
 - (a) ligating artificial long terminal repeats to the ends of a target nucleic acid sequence to form an artificial long terminal repeat vector,
 - (b) amplifying the artificial long terminal repeat vector by strand displacement replication primed by one or more strand displacement primers,
wherein the target nucleic acid sequence is amplified.
4. The method of claim 3 wherein the amplification of the artificial long terminal repeat vector is primed by a single strand displacement primer.
5. The method of claim 3 wherein the amplification is performed under substantially isothermic conditions.
6. The method of claim 3 wherein the amplification does not involve thermal cycling.
7. The method of claim 3 wherein step (b) does not include thermal cycling.
8. The method of claim 3 wherein the artificial long terminal repeats each have at least five repeat units.
9. The method of claim 7 wherein the artificial long terminal repeats each have at least 25 repeat units.

10. The method of claim 3 wherein the artificial long terminal repeat is produced by replicating a terminal repeat circle by rolling circle replication primed by a rolling circle replication primer.

11. The method of claim 10 wherein the artificial long terminal repeat is made double-stranded by performing the rolling circle replication in the presence of helicase, primase, ligase, and single-stranded DNA binding protein.

12. The method of claim 10 wherein the artificial long terminal repeat is made double-stranded by ligating together oligonucleotides hybridized to the artificial long terminal repeat strand made during the rolling circle replication.

13. A method of amplifying nucleic acid molecules, the method comprising:

(a) digesting a nucleic acid sample with a type II restriction endonuclease having an interrupted palindrome recognition sequence or a type IIS restriction enzyme to produce nucleic acid molecules with cohesive ends,

(b) ligating artificial long terminal repeats to the ends of the nucleic acid molecules to form artificial long terminal repeat vectors,

(c) amplifying the artificial long terminal repeat vectors by strand displacement replication primed by one or more strand displacement primers,

wherein the nucleic acid molecule is amplified.

14. The method of claim 13 wherein the amplification of the artificial long terminal repeat vector is primed by a single strand displacement primer.

15. The method of claim 13 wherein a set of artificial long terminal repeats is used in step (b), wherein each member of the set has a different cohesive end, and wherein the cohesive ends of the members of the set collectively include complements to all possible cohesive ends that can be generated by cleavage with the restriction endonuclease,

wherein the artificial long terminal repeat ligated on each end of the nucleic acid molecules depends on the sequences of the cohesive ends of each nucleic acid molecule.

16. The method of claim 15 wherein step (b) is performed as multiple separate reactions where each reaction has a different pair of artificial long terminal repeats.

17. The method of claim 13 wherein the nucleic acid sample is a sample of genomic nucleic acid.

18. A method of amplifying a target nucleic acid sequence, the method comprising:

- (a) ligation of multiple identical repeat units to form an artificial long terminal repeat,
- (b) ligating the artificial long terminal repeat to the ends of a target nucleic acid sequence to form an artificial long terminal repeat vector,
- (c) amplifying the artificial long terminal repeat vector by strand displacement replication primed by one or more strand displacement primers, wherein the target nucleic acid sequence is amplified.

19. The method of claim 18 wherein the amplification of the artificial long terminal repeat vector is primed by a single strand displacement primer.

20. A kit for amplifying a target nucleic acid sequence, the kit comprising an artificial long terminal repeat, wherein the artificial long terminal repeat comprises tandem repeat units and a tail sequence at one end, and a strand displacement primer, wherein the strand displacement primer is complementary to a sequence in, or straddling, the repeat units.

21. The kit of claim 20 further comprising a strand displacing DNA polymerase or a DNA polymerase and a compatible strand displacement factor.

22. A kit for amplifying a target nucleic acid sequence, the kit comprising a repeat circle, wherein the repeat circle is a single-stranded circular DNA molecule, a rolling circle replication primer comprising a sequence complementary to a sequence in the repeat circle, and a tail sequence, and a strand displacement primer, wherein the strand displacement primer is complementary to a sequence in, or straddling, the repeat units.

23. The kit of claim 22 further comprising a strand displacing DNA polymerase or a DNA polymerase and a compatible strand displacement factor.

24. The kit of claim 23 further comprising helicase, primase, ligase, and single-stranded DNA binding protein.

25. The kit of claim 23 further comprising ligase and linear oligonucleotides matching the sequence of the repeat circle.




Figure 1





Figure 2

Amplification of 14000 bp cDNA insert with 600-repeat ALTR



Amplification of 65 kb DNA Insert with 48-repeat ALTR




Figure 4

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/21087

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 19193 A (UNIV YALE) 29 May 1997 (1997-05-29)	22-25
Y	the whole document	1-21
X	LIZARDI P M ET AL: "MUTATION DETECTION AND SINGLE-MOLECULE COUNTING USING ISOTHERMAL ROLLING-CIRCLE AMPLIFICATION" NATURE GENETICS, US, NEW YORK, NY, vol. 19, no. 3, July 1998 (1998-07), pages 225-232, XP000856939 ISSN: 1061-4036	22-25
Y	the whole document	1-21
X	WO 97 20948 A (KOCH JOERN ERLAND) 12 June 1997 (1997-06-12)	22-25
Y	the whole document	1-21
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

24 February 2000

Date of mailing of the international search report

09/03/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hagenmaier, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/21087

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92 01813 A (SYNGENE INC) 6 February 1992 (1992-02-06)	22-25
Y	the whole document	1-21
X	US 5 714 320 A (KOOL ERIC T) 3 February 1998 (1998-02-03)	22,23
Y	the whole document	1-21
Y	EP 0 640 691 A (BECTON DICKINSON CO) 1 March 1995 (1995-03-01)	1-21
Y	the whole document	
Y	WO 98 39485 A (UNIV MICHIGAN ; LANGMORE JOHN P (US); MAKAROV VLADIMIR L (US)) 11 September 1998 (1998-09-11)	1-21
Y	the whole document	
Y	UNRAU P ET AL: "NON-CLONING AMPLIFICATION OF SPECIFIC DNA FRAGMENTS FROM WHOLE GENOMIC DNA DIGEST USING DNA 'INDEXERS'" GENE, 1 January 1994 (1994-01-01), XP002054436	13-17
A	the whole document	
A	WHITE M J ET AL: "CONCATEMER CHAIN REACTION: A TAQ DNA POLYMERASE-MEDIATED MECHANISM FOR GENERATING LONG TANDEM REPETITIVE DNA SEQUENCES" ANALYTICAL BIOCHEMISTRY, US, ACADEMIC PRESS, SAN DIEGO, CA, vol. 199, no. 2, 1 December 1991 (1991-12-01), pages 184-190, XP000236491 ISSN: 0003-2697	
A	the whole document	
A	ZHANG ET AL.: "AMPLIFICATION OF TARGET-SPECIFIC, LIGATION-DEPENDENT CIRCULAR PROBE" GENE, vol. 211, 1998, pages 277-285, XP002130920	
A	the whole document	
A	WO 97 42346 A (TEPNEL MEDICAL LTD ; MINTER STEPHEN JOHN (GB); OULTRAM JOHN DOUGLAS) 13 November 1997 (1997-11-13)	
A	the whole document	
A	WO 96 00795 A (KALYX BIOSCIENCES INC ; PANDIAN SITHIAN (CA); AW ENG JOM (CA); SMIT) 11 January 1996 (1996-01-11)	
	the whole document	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/21087

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9719193 A	29-05-1997	US 5854033 A	29-12-1998
		AU 714486 B	06-01-2000
		AU 1024097 A	11-06-1997
		EP 0862656 A	09-09-1998
WO 9720948 A	12-06-1997	AU 704750 B	06-05-1999
		AU 7691796 A	27-06-1997
		CA 2239287 A	12-06-1997
		EP 0868530 A	07-10-1998
WO 9201813 A	06-02-1992	AU 649066 B	12-05-1994
		AU 8417391 A	18-02-1992
		EP 0542874 A	26-05-1993
		JP 6500014 T	06-01-1994
		NO 930235 A	22-01-1993
US 5714320 A	03-02-1998	NONE	
EP 0640691 A	01-03-1995	US 5470723 A	28-11-1995
		AU 686169 B	05-02-1998
		AU 6888894 A	09-03-1995
		BR 9403324 A	11-04-1995
		CA 2129690 A	25-02-1995
		JP 2814422 B	22-10-1998
		JP 7163396 A	27-06-1995
		SG 44897 A	19-12-1997
		US 5561044 A	01-10-1996
		US 5736365 A	07-04-1998
WO 9839485 A	11-09-1998	AU 6544598 A	22-09-1998
WO 9742346 A	13-11-1997	AU 2646497 A	26-11-1997
WO 9600795 A	11-01-1996	CA 2126952 A	29-12-1995
		AU 2709995 A	25-01-1996
		DE 69514521 D	17-02-2000
		EP 0770142 A	02-05-1997
		JP 10508741 T	02-09-1998
		US 5627030 A	06-05-1997